Chemoprevention of colorectal cancer;A vastagbélrák kemoprofilaxisa

Orvosi Hetilap

Volumn 145, Issue 12, 2004, Pages 603-610

  Herszényi, László ^a,b   Juhász, Márk ^a   Prónai, László ^a   Tulassay, Zsolt ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b NONE   (Hungary)

Author keywords

Adenoma; Aspirin; Chemoprevention; Colorectal cancer; Coxibs; Cyclooxygenase; Familial adenomatous polyposis; Nonsteroidal anti inflammatory drugs

Indexed keywords

ACETYLSALICYLIC ACID; CYCLOOXYGENASE 2 INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; PROSTAGLANDIN SYNTHASE INHIBITOR;

ADENOMATOUS POLYP; CANCER INCIDENCE; CANCER MORTALITY; CANCER PREVENTION; CANCER SCREENING; CANCER STAGING; CARCINOGENESIS; CHEMOPROPHYLAXIS; COLORECTAL ADENOMA; COLORECTAL CANCER; DRUG EFFECT; DRUG MECHANISM; HUMAN; MORTALITY; REVIEW; ANIMAL; COLON POLYPOSIS; COLORECTAL TUMOR; INCIDENCE;

ADENOMATOUS POLYPOSIS COLI; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTICARCINOGENIC AGENTS; ANTINEOPLASTIC AGENTS; ASPIRIN; COLORECTAL NEOPLASMS; CYCLOOXYGENASE INHIBITORS; HUMANS; INCIDENCE;

EID: 2942594708     PISSN: 00306002     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (50)

1. Alberts, D. S., Martinez, M. E., Roe, D. J. és mtsai: Lack of effect of a high-fiber cereal supplement on the recurrence of colorectal adenomas. Phoenix Colon Cancer Prevention Physicians' Network. N. Engl. J. Med., 2000, 342, 1156-1162.
2. Alberts, D. S.: Reducing The risk of colorectal cancer by intervening in the process of carcinogenesis: a status report. Cancer. J., 2002, 8, 208-221.
3. Baron, J. A., Cole, B. F., Sandler, R. S. és mtsai: A randomized trial of aspirin to prevent colorectal adenomas. N. Engl. J. Med., 2003, 348, 891-899.
4. Baron, J. A., Beach, M., Mandel, J. S. és mtsai: Calcium supplements for the prevention of colorectal adenomas. Calcium Polyp Prevention Study Group. N. Engl. J. Med., 1999, 340, 101-107.
5. Blanke, C. D.: Celecoxib with chemotherapy in colorectal cancer. Oncology, 2002, 16, 17-21.
6. Bonithon-Kopp, C., Kronborg, O., Giacosa, A. és mtsai: Calcium and fibre supplementation in prevention of colorectal adenoma recurrence: a randomised intervention trial. Lancet, 2000, 356, 1300-1306.
7. Cairns, S., Scholefied, J. H.: Guidelines for colorectal cancer screening in high risk groups. Gut, 2002, 51 (Suppl. 5), 1-2.
8. Calle, E. E., Miracle-McMahill, H. L., Thun, M. J. és mtsai: Estrogen replacement therapy and risk of fatal colon cancer in a prospective cohort of postmenopausal women. J. Natl. Cancer. Inst., 1995, 87, 517-523.
9. Chapple, K. S., Cartwright, E. J., Hawcroft, G. és mtsai: Localization of cyclooxygenase-2 in human sporadic colorectal adenomas. Am. J. Pathol., 2000, 156, 545-553.
10. Chau, I.: Cyclooxygenase inhibition in cancer- a blind alley or a new therapeutic reality? N. Engl. J. Med., 2002, 346, 1085-1087.
11. Chinthalapally, V. R., Indriane, C., Simi, B., és mtsai: Chemopreventive properties of a selective inducible nitric oxide synthase inhibitor in colon carcinogenesis, administered alone or in combination with celecoxib, a selective cyclooxygenase-2 inhibitor. Cancer. Res., 2002, 62, 165-170.
12. Dannenberg, A. J., Altorki, N. K., Boyle, J. O. és mtsai: Cyclooxygenase 2: a pharmacological target for the prevention of cancer. Lancet-Oncology, 2001, 2, 544-551.
13. Giardiello, F. M., Hamilton, S. R., Krush, A. J. és mtsai: Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N. Engl. J. Med., 1993, 328, 1313-1316.
14. Giardiello, F. M., Yang, V. W., Hylind, L. M. és mtsai: Primary chemoprevention of familial adenomatous polyposis with sulindac. N. Engl. J. Med. 2002, 346, 1054-1059.
15. Giovanucci, E.: An updated review of the epidemiological evidence that cigarette smoking increases risk of colorectal cancer. Cancer. Epidemiol. Biomarkers. Prev., 2001, 10, 725-731.
16. Giovanucci, E.: Modifiable risk factor for colon cancer. Gastroenterol. Clin. North. Am. 2002, 31, 925-943.
17. Giovanucci, E., Rimm, E. B., Stampfer, M. J. és mtsai: Aspirin use and the risk for colorectal cancer and adenoma in male Health Professionals. Ann. Intern. Med., 1994, 121, 241-246.
18. Giovanucci, E., Egan, K. M., Hunter, D. J. és mtsai: Aspirin and the risk of colorectal cancer in women. N. Engl. J. Med., 1995, 333, 609-614.
19. Giovanucci, E., Stampfer, M. J., Colditz, G. A. és mtsai: Multivitamin use, folate, and colon cancer in women in the Nurses Health Study. Ann. Intern. Med., 1998, 129, 517-524.
20. Greenberg, E. R., Baron, J. A., Freeman, D. H. J. és mtsai: Reduced risk of large-bowel adenomas among aspirin users: the Polyp Prevention Study Group. J. Natl. Cancer Inst., 1993, 85, 912-916.
21. Gridley, G., McLaughlin, J. K., Ekbom, A. és mtsai: Incidence of cancer among patients with rheumatoid arthritis. J. Natl. Cancer Inst., 1993, 85, 307-311.
22. Grodstein, F., Martinez, M.E., Platz, E.A. és mtsai: Postmenopausal hormone use and risk for colorectal cancer and adenoma. Ann. Intern. Med., 1998, 128, 705-712.
23. Grösch, S., Tegeder, I., Niederberger, E. és mtsai: COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib. FASEB. 2001, 15, 2742-2744.
24. Hawk, E. T., Viner, J. L., Dannenberg, A. és mtsai: COX-2 in cancer- a player that's defining the rules. J. Natl. Cancer, Inst, 2002, 94, 545-546.
25. He, T. C., Chan, T. A., Vogelstein, B. és mtsai: PPAR-delta is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell, 1999, 99, 335-345.
26. Imperiale, T. F.: Aspirin and the prevention of colorectal cancer. N. Engl. J. Med, 2003, 348, 879-880.
27. Jacoby, R. F., Seibert, K., Cole, C. E. és mtsai: The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the Min mouse model of adenomatous polyposis. Cancer Res., 2000, 60, 5040-5044.
28. Jacoby, R. F., Cole, C. E., Lubet, R. A. és mtsai: Effects of the nonspecific COX1/2 inhibitor piroxicam and the ornithine decarboxylase inhibitor difluoromethylornithine (DFMO) on development of intestinal tumors in mice bearing germline alterations in the Msh2 or APC genes. Proc. Am. Assoc. Cancer. Res., 2001, 42, 263-264.
29. Labayle, D., Fisher, D., Vielh, P. és mtsai: Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology, 1991, 101, 635-639.
30. Marx, J.: Anti-inflammatories inhibit cancer growth-but how? Science, 2001, 291, 581-582.
31. Nugent, K. P., Farmer, K. C., Spigelman, A. D. és mtsai: Randomized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposis. Br. J. Surg., 1993, 80, 1618-1619.
32. Oshima, M., Murai, N., Kargman, S. és mtsai: Chemoprevention of intestinal polyposis in the Apc-delta 716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor. Cancer Res., 2001, 61, 1733-1740.
33. Ottó Sz., Kásler M.: Rákmortalitás és -incidencia hazánkban, az európai adatok tükrében. Magyar Onkol., 2002, 46, 111-117.
34. Papp, J.: A colorectalis carcinoma és a kemoprevenció. Orvostovábbképzo Szemle 2000, november (különszá m), 10-19.
35. Pardi, D. S., Loftus, Jr. E., Kremers, W. K. és mtsai: Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology, 2003, 124, 889-893.
36. Pasi, J. A., Robert, M. J.: Primary care: chemoprevention of colorectal cancer. N. Engl. J. Med., 2000, 342, 1960-1968.
37. Phillips, R. K. S., Wallace, M. H., Lynch, P. M. és mtsai: A randomized, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis. Gut, 2002, 50, 857-860.
38. Rahme, E., Barkun, A. N., Toubouti, Y. és mtsai: The cyclooxygenase-2-selective inhibitors rofecoxib and celecoxib prevent colorectal neoplasia occurrence and recurrence. Gastroenterology, 2003, 125, 404-412.
39. Randall, W. B.: Colon cancer screening. Gastroenterology, 2000, 119, 837-853.
40. Ransohoff, D. F., Sandler, R. S.: Screening for colorectal cancer. N. Engl. J. Med., 2002, 346, 40-44.
41. Sandler, R. S., Halabi, S., Baron, J. A. és mtsai: A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N. Engl. J. Med., 2003, 348, 883-890.
42. Schatzkin, A., Lanza, E., Corle, D. és mtsai: Lack of effect of a low-fat, high-fiber diet on the recurrence of colorectal adenoma. Polyp Prevention Trial Study Group. N. Engl. J. Med., 2000, 342, 1149-1155.
43. Schreinemacher, D. M., Everson, R. B.: Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology, 1994, 5, 138-146.
44. Smalley, W., Ray, W. A., Daugherty, J. és mtsai: Use of nonsteroidal anti-inflammatory drugs and incidence of colorectal cancer. A population-based study. Arch. Intern. Med., 1999, 159, 161-165.
45. Smith, R. A., Cokkinides, V., Eyre, H. J.: American Cancer Society Guidelines for the early detection of cancer. Ca. Cancer. J. Clin., 2003, 53, 27-43.
46. Steinbach, G., Lynch, P. M., Phillips, R. K. S. és mtsai: The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N. Engl. J. Med., 2000, 342, 1946-1952.
47. Thun, M. J., Namboodiri, M. M., Calle, E. F. és mtsai: Aspirin use and risk of fatal cancer. Cancer. Res., 1993, 53, 1322-1327.
48. Újszászy L.: A vastagbélrák prevenciója és korai felismerése. Eur. J. Gastroenterol. Hepatol. (magyar kiadás) 2001, 1, 3-8.
49. Zhang, L., Yu, J., Park, B. H. és mtsai: Role of BAX in the apoptotic response to anticancer agents. Science, 2000, 290, 989-992.
50. Yamazaki, R., Kusunoki, N., Matsuzaki, T. és mtsai: Selective cyclooxygenase-2 inhibitors show a differential ability to inhibit proliferation and induce apoptosis of colon adenocarcinoma cells. FEBS Lett., 2002, 6, 278-284.